Global Clinical Diagnostics Outlook, 2024

出版日: | 発行: Frost & Sullivan | ページ情報: 英文 91 Pages | 納期: 即日から翌営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
出版日: 2024年04月18日
発行: Frost & Sullivan
ページ情報: 英文 91 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次


COVID-19パンデミックの終息に伴い、臨床診断業界が集中型から分散型検査モデルへの移行を続ける中、医療プロバイダーはその能力の大半を予防ヘルスケアと精密医療に向けています。世界的に、2024年は臨床検査業界にとって利益をもたらす年になると予想され、2029年まで持続的な成長が続くと思われます。主な促進要因はPOCTと分子診断部門であり、Frost & Sullivanは2024年にさらに力強い回復を遂げると予測しています。




  • 分析ハイライト
  • 2023年の臨床診断業界:予測 vs. 実績
  • 2024年の主要な臨床診断の予測


  • なぜ成長が難しくなっているのか?
  • The Strategic Imperative 8(TM)
  • 臨床診断業界に対する主要な戦略的インペラティブの影響
  • Growth Pipeline Engine(TM)を促進する成長機会



収益動向 - 2024年

  • 予測前提条件:臨床診断業界
  • 臨床診断業界、セグメント別
  • 収益予測、サブセグメント別
  • 収益予測、セグメント別:集中検査
  • 収益予測、セグメント別:紹介・周辺、分散型検査
  • 収益予測、地域別
  • 収益割合予測、地域別
  • 収益予測分析、地域別
  • 競合環境
  • 収益シェア
  • 収益シェア分析
  • 競合マトリックス


  • 注目すべきM&A
  • M&A:過去の分析

予測トップ5 - 2024年

  • 予測1:長期的な消費者行動の変化が自己採取検査への拡大を支援
  • 予測2:人手不足が引き続きラボオートメーションの2桁成長率を牽引
  • 予測3:NGSと専門的バイオインフォマティクスツールの導入が製薬企業のイノベーションを支援
  • 予測4:ctDNA解析がプレシジョンオンコロジーにおけるMRD検査の適用を拡大
  • 予測5:AIに焦点を当てたスタートアップ企業との提携が、臨床セグメントにおけるAIベースのデジタルパソロジーの採用を推進

業界スナップショット - 2024年

臨床化学・イムノアッセイ - 2024年

  • 臨床化学・イムノアッセイ業界スナップショット
  • 臨床化学・イムノアッセイ業界:注目企業

分子診断 - 2024年

POCT - 2024年

組織診断 - 2024年年


  • 成長機会1:デジタル診断サービスへのシフト
  • 成長機会2:臨床化学・イムノアッセイの新興市場への拡大
  • 成長機会3:遺伝学・心血管疾患の分子診断における予測検査
  • 成長機会4:臨床現場における分子POCT
  • 成長機会5:イムノアッセイ、STI、AMRアプリケーション向けマルチプレックスPOCT



Product Code: KA03-55

Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which Frost & Sullivan expects to rebound even more strongly in 2024.

This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry's decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.

Table of Contents

Analysis Highlights

  • Analysis Highlights
  • The 2023 Clinical Diagnostics Industry: Forecast vs. Actual
  • Top Clinical Diagnostics Predictions for 2024

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Clinical Diagnostics Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Environment

  • Segmentation
  • Growth Environment

Macroeconomic Factors

  • Top 10 Trends for 2024
  • Top 10 Growth Opportunities
  • 1. Global GDP Growth-Mild Global Growth Slowdown from 3.0% in 2023 to 2.6% in 2024 as Key Economies Lose Growth Momentum
  • 2. Inflation and Interest Rates-Headline Inflation to Continue to Decline; H2 2024 Shift Toward Rate Cuts for Advanced Economies
  • 3. Currency Trajectory-Dollar to Remain Strong in H1 2024; Emerging Market Currencies to Get Boost from Q3 2024 Onwards
  • 4. Labor Market-Moderate Unemployment Uptick; Positive Expectations Over Market Sentiment to Support Labor Hoarding
  • 5. Oil Markets-Q1 OPEC+ Oil Production Cuts; Non-OPEC Production to Rise
  • 6. Critical Minerals Supplies-Need for Economic Resiliency to Bolster Cross-border and Cross-industry Partnerships
  • 7. North America-Economic Slowdown Amidst Discretionary Spending Pullback and Elevated Interest Rates
  • 8. Western Europe-Moderate Growth Pick-up as Inflation Headwinds Ease Gradually; Rebuilding Fiscal Buffers to Take Precedence
  • 9. Middle East-Non-oil Growth Driven by Economic Diversification to Limit Pullback Caused by a Slowdown in Global Oil Markets
  • 10. Asia-Emerging Economies to Drive Growth Momentum; Fiscal Measures to Support Chinese Economic Recovery

Revenue Trends-2024

  • Forecast Assumptions: Clinical Diagnostics Industry
  • Clinical Diagnostics Industry by Segment
  • Revenue Forecast by Subsegment
  • Revenue Forecast by Segment: Centralized Testing
  • Revenue Forecast by Segment: Referral & Peripheral and Decentralized Testing
  • Revenue Forecast by Region
  • Percent Revenue Forecast by Region
  • Revenue Forecast Analysis by Region
  • Competitive Environment
  • Revenue Share
  • Revenue Share Analysis
  • Competitor Matrix

Mergers and Acquisitions

  • Notable M&As in 2023
  • M&As: Historical Analytics

Top 5 Predictions-2024

  • Prediction 1: Long-term Change in Consumer Behavior Supports Expansion into Self-collection Testing
  • Prediction 2: Staff Shortages Continue to Drive Double-digit Lab Automation Growth Rate
  • Prediction 3: Adoption of NGS and Specialized Bioinformatics Tools Will Support Pharma Innovation
  • Prediction 4: ctDNA Analysis Will Expand the Application of MRD Testing for Precision Oncology
  • Prediction 5: Partnerships with AI-focused Start-ups to Promote Adoption of AI-based Digital Pathology in Clinical Segments

Industry Snapshot-2024

  • 2024 Industry Snapshot

Clinical Chemistry and Immunoassays-2024

  • Clinical Chemistry and Immunoassays Industry Snapshot
  • Clinical Chemistry and Immunoassays Industry: Companies to Watch

Molecular Diagnostics-2024

  • Molecular Diagnostics Industry Snapshot
  • Molecular Diagnostics Industry: Companies to Watch


  • POCT Industry Snapshot
  • POCT Industry: Companies to Watch

Tissue Diagnostics-2024

  • Tissue Diagnostics Industry Snapshot
  • Tissue Diagnostics Industry: Companies to Watch

Growth Opportunity Universe

  • Growth Opportunity 1: Shift toward Digital Diagnostics Services
  • Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets
  • Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases
  • Growth Opportunity 4: Molecular POCT in Clinical Settings
  • Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications


  • Conclusions and Future Outlook

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer